Assertio Therapeutics (ASRT) Tops Q1 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- Wall St set to fall at open as yields and oil rebound; Fed minutes in focus
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Musk rules out TSMC role in Terafab operations; Intel gains
- U.S. 10-year yield climb revives dotcom-era parallels: UBS weighs in
- HubSpot to cut 7% of workforce in restructuring plan
- Caribou Biosciences to halt CAR-T programs, explore sale
- Emera and Canadian Utilities agree to merge in $72B all-share deal
- Stryker names Spencer Stiles as CEO, Lobo moves to chair
- S&P 500, Nasdaq reach record closing highs as focus pivots to earnings
Assertio Therapeutics Announces First-Quarter 2019 Financial Results
May 8, 2019 4:02 PM EDT-- Reports Neurology Franchise Net Sales of $26.3 million --
-- Commercialization Agreement Revenues of $30.9 million --
-- Raises 2019 Earnings Guidance Range and Confirms Neurology Franchise Net Sales Guidance --
-- Significant Debt Reduction --
LAKE FOREST, Ill., May 08, 2019 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ: ASRT) today reported financial results for the quarter ended March 31, 2019, and provided an update on its business performance and strategic initiatives.
First-Quarter Financial Highlights:(unaudited)
... More


